Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.

Ka Lum Taimur Bhatti Silas Holland Mark Guthrie Stephanie Sassman

J Law Med Ethics

Ka Lum, Ph.D., M.B.A., was the Head of Global Pricing & Market Access of Immunology, Infectious Diseases and Ophthalmology at Genentech, a member of the Roche Group. She holds a Bachelor of Science in Chemistry, a Bachelor of Arts in Applied Mathematics, a Doctor of Philosophy in Chemistry, and a Master of Business Administration from UC Berkeley. Taimur Bhatti, M.Sc., is an International Payer Strategy Leader in Infectious Diseases at Hoffmann-La Roche. He holds a Bachelor of Science in Biomedical Engineering from Duke University and a Master in Science in Health Economics/Pharmaceutical Sciences from the University of Toronto (Canada). Silas Holland, M.P.H., M.A., is a Director of Global Public Policy at Merck and Co., Inc. responsible for infectious disease global health policy, primarily focusing on antibiotics/antifungals. He holds a Bachelor of Science in Biology from Duke University and has postgraduate degrees in education (Loyola Marymount University) and public health (University of Pretoria, South Africa). Mark Guthrie, M.B.A., is the Global Pricing and Market Access Pipeline Head for Immunology, Infectious Disease and Ophthalmology at Genentech, a member of the Roche Group. He has a Master of Business Administration in Healthcare Management from the University of Baltimore and a Bachelor of Arts in Economics from Denison University. Stephanie Sassman is a Lifecycle Leader in Immunology at Genentech, a member of the Roche Group. She holds a Bachelor of Business Administration from the University of Texas at Austin.

Published: June 2018

The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.

Download full-text PDF	Source
http://dx.doi.org/10.1177/1073110518782917	DOI Listing

Publication Analysis

Top Keywords

diagnosis confirmation

confirmation model

value-based pricing

novel antibiotics

model

model value-based

pricing model

model inpatient

inpatient novel

antibiotics diagnosis

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!